A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability and ORR as the primary study objectives and indicators, and plans to enroll about 50-60 patients.
Advanced Hepatocellular Carcinoma (HCC)
COMBINATION_PRODUCT: Toripalimab combined with Bevacizumab
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Frequency table will be used to summarize occurrence of each treatment-emergent AE, Up to 2 years|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Number and incidence of abnormal laboratory examinations by treatment group., Up to 2 years|ORR, The rate of participants that achieve either a complete response (CR) or a partial response (PR)., Up to 2 years
DoR, The time from the first assessment of CR or PR to the first assessment of PD or death due to any cause., Up to 2 years|DCR, The percentage of cases with remission (PR + CR) and stable lesions (SD) after treatment was assessable., Up to 2 years|TTP, time from the start of treatment to progression of diease., Up to 2 years|PFS, PFS is defined as time from the start of treatment to progression of disease or death., Up to 2 years|Overall survival (OS), Overall survival is defined as time from the start of treatment until death due to any reason., Up to 2 years
PD-L1, Correlation between PD-L1 expression level in tumor tissue, proportion of strong positive expression of PD-L1, Up to 2 years|TMB, Correlation betweenTumor mutation burden (TMB) and the efficacy, Up to 2 years|PK, Pharmacokinetic profile in HCC patients of observed maximum plasma concentration, Up to 2 years|ADA, Analysis of anti-drug antibody (ADA) during treatment., Up to 2 years
This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability and ORR as the primary study objectives and indicators, and plans to enroll about 50-60 patients.